Business Context and Reporting Period
This Form 8-K Current Report was filed by Biocardia, Inc. on September 18, 2024. The filing addresses a specific regulatory event regarding the company's continued listing status on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate governance and listing compliance event.
Material Changes
The primary material event reported is the resolution of a listing deficiency:
- Biocardia received formal written notice from Nasdaq confirming compliance with Listing Rule 5550(b)(1) (the "Equity Rule").
- This compliance satisfies the requirements of a Hearings Panel decision dated May 13, 2024.
- The Panel has determined to continue the listing of Biocardia's securities on The Nasdaq Stock Market and has closed the matter.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the listing status. The filing notes that while the specific matter is closed, Nasdaq will continue to monitor the Company's ongoing compliance with continued listing requirements. No forward-looking guidance, new risks, or unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading status of Biocardia (BCDA) on The Nasdaq Capital Market to confirm the listing remains active.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the compliance process.
- Monitor future filings for any new notices regarding continued listing requirements.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.